These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33431141)

  • 1. Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective.
    Annemans L; Beutels P; Bloom DE; De Backer W; Ethgen O; Luyten J; Van Wilder P; Willem L; Simoens S
    Value Health; 2021 Jan; 24(1):105-111. PubMed ID: 33431141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study.
    van der Putten IM; Evers SM; Deogaonkar R; Jit M; Hutubessy RC
    BMC Public Health; 2015 Apr; 15():356. PubMed ID: 25881178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.
    Nymark LS; Sharma T; Miller A; Enemark U; Griffiths UK
    Vaccine; 2017 Dec; 35(49 Pt B):6828-6841. PubMed ID: 29146380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries.
    Deogaonkar R; Hutubessy R; van der Putten I; Evers S; Jit M
    BMC Public Health; 2012 Oct; 12():878. PubMed ID: 23072714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness.
    Luyten J; Beutels P
    Health Aff (Millwood); 2016 Feb; 35(2):212-8. PubMed ID: 26858372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of economic evaluations of vaccination programs in mainland China: Are they sufficient to inform decision making?
    Pan XF; Griffiths UK; Pennington M; Yu H; Jit M
    Vaccine; 2015 Nov; 33(46):6164-72. PubMed ID: 26435189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; Newall AT
    Pharmacoeconomics; 2016 Aug; 34(8):723-31. PubMed ID: 26914091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A visual approach to the economic evaluation of vaccines: opening the health economic black box.
    Kung E; Bufali MV; Morton A
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):985-994. PubMed ID: 33682576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination.
    Nandi A; Shet A
    Hum Vaccin Immunother; 2020 Aug; 16(8):1900-1904. PubMed ID: 31977283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries.
    Chang AY; Riumallo-Herl C; Perales NA; Clark S; Clark A; Constenla D; Garske T; Jackson ML; Jean K; Jit M; Jones EO; Li X; Suraratdecha C; Bullock O; Johnson H; Brenzel L; Verguet S
    Health Aff (Millwood); 2018 Feb; 37(2):316-324. PubMed ID: 29401021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
    Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
    Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Strengthen the studies on vaccine safety surveillance and economic assessment in China: not a moment too soon].
    Zhang J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):661-663. PubMed ID: 31288334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considering economic analyses in the revision of the preventive vaccination law: a new direction for health policy-making in Japan?
    Akazawa M; Yongue J; Ikeda S; Satoh T
    Health Policy; 2014 Oct; 118(1):127-34. PubMed ID: 25139708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR.
    Sevilla JP; Bloom DE; Cadarette D; Jit M; Lipsitch M
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12911-12919. PubMed ID: 30559203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.